Biopeak, a Bengaluru-based health-tech startup focused on longevity and preventive healthcare, has raised USD 2.7 million in a follow-on funding round led by NKSquared, the investment vehicle of Zerodha co-founder Nikhil Kamath.
This represents Kamath’s second investment in the company, following an earlier contribution of USD 1.43 million in August 2024.
The fresh capital will be deployed to widen Biopeak’s operational footprint, including the establishment of a new flagship clinic, strengthening its diagnostic capabilities, enhancing proprietary artificial intelligence tools, supporting research initiatives, and scaling clinical programmes.
Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak delivers personalised health plans designed to extend healthspan — the portion of life spent in good health. Its model blends advanced molecular diagnostics, imaging technologies, and AI-driven insights to generate tailored clinical recommendations.
The startup’s approach integrates a range of diagnostic techniques, including organic acid profiling, microbiome mapping, whole-exome functional genomics, salivary cortisol rhythm analysis, and imaging modalities such as MRI, CT, DXA, and ECHO. These inputs feed into specialist-led care programmes that cover nutrition, sleep, stress management and overall well-being.
Biopeak’s in-house clinics target high achievers, executives and women, designing interventions that combine wearable data, expert teams and AI insights tailored to Indian health profiles and disease patterns. The company opened its first clinic in Bengaluru in 2025 and plans to launch a second location in the coming month in response to growing demand for structured longevity services.
The latest funding round underscores investor confidence in Biopeak’s preventive care approach at a time when demand for personalised and proactive health management solutions is rising in India’s evolving healthcare landscape.
